Clinical Trial Update: Real-world Studies of CDK4/6 Inhibitors

View source ↗

Summary

This update notes ongoing real-world studies evaluating CDK4/6 inhibitors in breast cancer, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (Verzenio) (abemaciclib)
• Palbociclib (Ibrance) (palbociclib)
• Ribociclib (Kisqali) (ribociclib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Breast Cancer | Status: RECRUITING